• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Regen BioPharma, Eli Lilly partner on open innovation drug discovery program

Regen BioPharma, Eli Lilly partner on open innovation drug discovery program

July 5, 2016
CenterWatch Staff

Regen BioPharma has entered into a definitive agreement with Eli Lilly which allows Regen to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest. 

The agreement also grants to Lilly an option to negotiate an agreement with Regen including but not restricted to a compound purchase agreement, a license agreement or a research collaboration agreement for further research and development of material of mutual interest. 

"Lilly's Open Innovation Drug Discovery Program is visionary," said Harry Lander, Ph.D., MBA, president and chief scientific officer of Regen BioPharma. "They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals." 

Regen will examine 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program as it attempts to identify activators and inhibitors of this protein. Regen will share the experimental data with Lilly and the two companies will jointly decide on next steps. 

NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patents covering means of manipulating NR2F6 in oncology and immunology. Issued US Patent # 9091696 was granted to Regen and covers means of screening small molecules such as is being done in this program. Cancer, as well as autoimmune diseases such as lupus, rheumatoid arthritis and irritable bowel syndrome, is likely to be controlled by modifying NR2F6 activity. 

Regen is currently in the process of screening more than 70,000 compounds in an effort to identify activators and inhibitors of NR2F6. Two activators have been identified and preliminary work on inhibitors is currently underway. 

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing